Y-mAbs Therapeutics, Inc. (YMAB) Financials
Stock symbol YMAB is outdated, potentially delisted? Maybe it is available on other exchange?
YMAB Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2025 | 117.2 million | 29.7 million |
| March 31, 2025 | 112.6 million | 23.2 million |
| Dec. 31, 2024 | 119.9 million | 27.9 million |
| Sept. 30, 2024 | 120.9 million | 28.5 million |
YMAB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2025 | 1.7 million | 2.9 million |
| March 31, 2025 | -7.0 million | 3.3 million |
| Dec. 31, 2024 | -1.9 million | 3.1 million |
| Sept. 30, 2024 | -10.7 million | 4.2 million |
YMAB Net Income
No data available :(
YMAB Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2025 | 62.3 million | 2.6 million | 3.1 million |
| March 31, 2025 | 60.3 million | 148000 | 603000 |
| Dec. 31, 2024 | 67.2 million | 190000 | 820000 |
| Sept. 30, 2024 | 68.1 million | 299000 | 1.1 million |
YMAB Shares Outstanding
YMAB Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2025 | - | 11.1 million | 11.3 million | - |
| March 31, 2025 | 127000 | 11.4 million | 13.1 million | - |
| Dec. 31, 2024 | - | 12.2 million | 12.4 million | - |
| Sept. 30, 2024 | - | 11.2 million | 13.6 million | - |
YMAB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2025 | 19.5 million | 2.7 million |
| March 31, 2025 | 20.9 million | 3.0 million |
| Dec. 31, 2024 | 26.5 million | 7.8 million |
| Sept. 30, 2024 | 18.5 million | 2.2 million |
YMAB Revenue by Segment
Graph available only for paid members. Upgrade to see it.
YMAB
Price: $8.61
52 week price:
Earnings Per Share: -0.50 USD
P/E Ratio: -17.14
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 294900
Market Capitalization: 389.4 million